section name header

Pronunciation

pen-tox-IF-i-lin

Classifications

Therapeutic Classification: blood viscosity reducing agent

Indications

REMS


Action

  • Increases the flexibility of RBCs by increasing levels of cyclic adenosine monophosphate (cAMP).
  • Decreases blood viscosity by inhibiting platelet aggregation and decreasing fibrinogen.
Therapeutic effects:
  • Increased blood flow.

Pharmacokinetics

Absorption: Well absorbed following oral administration; food absorption.

Distribution: Bound to RBC membrane. Enters breast milk.

Metabolism/Excretion: Metabolized by RBCs and the liver.

Half-Life: 25–50 min.

Time/Action Profile

(improvement in blood flow)

ROUTEONSETPEAKDURATION
PO2–4 wk8 wk8 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: angina, arrhythmias, edema, flushing, hypotension

EENT: blurred vision

GI: abdominal discomfort, belching, bloating, diarrhea, dyspepsia, flatus, nausea, vomiting

Neuro: agitation, dizziness, drowsiness, headache, insomnia, nervousness, tremor

Resp: dyspnea

Misc: ANAPHYLAXIS

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

TRENtal